The impact of pharmacogenetics of metabolic enzymes and transporters on the pharmacokinetics of telmisartan in healthy volunteers

Pharmacogenetics and Genomics

Volumn 21, Issue 9, 2011, Pages 523-530

  Yamada, Akihiro ^a   Maeda, Kazuya ^a   Ishiguro, Naoki ^b   Tsuda, Yasuhiro ^b   Igarashi, Takashi ^b   Ebner, Thomas ^d   Roth, Willy ^d   Ikushiro, Shinichi ^c   Sugiyama, Yuichi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b NIPPON BOEHRINGER INGELHEIM CO LTD   (Japan)

^c TOYAMA PREFECTURAL UNIVERSITY   (Japan)

^d BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

glucuronidation; pharmacokinetics; telmisartan; UGT1A1*28; UGT1A3

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CARRIER PROTEIN; DRUG METABOLIZING ENZYME; ESTRADIOL 3 GLUCURONIDE; GLUCURONIDE; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A3; GLUCURONOSYLTRANSFERASE 1A7; GLUCURONOSYLTRANSFERASE 1A8; GLUCURONOSYLTRANSFERASE 1A9; GLUCURONOSYLTRANSFERASE 2B7; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS TELMISARTAN; ISOENZYME; MICOMBI; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; ORGANIC ANION TRANSPORTER 1; PROTEIN OATP1B1; PROTEIN OATP1B3; RECOMBINANT ENZYME; TELMISARTAN; TELMISARTAN GLUCURONIDE; UNCLASSIFIED DRUG;

ADULT; ALLELE; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CLEARANCE; DRUG GLUCURONIDATION; DRUG METABOLISM; GENE FUNCTION; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; LIVER CELL; LIVER MICROSOME; LIVER MICROSOME METABOLISM; MALE; NORMAL HUMAN; PHARMACOGENETICS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; WILD TYPE;

EID: 85027955748     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e3283482502     Document Type: Article

References (31)

1. Wienen W, Entzeroth M, Meel JC, Stangier J, Busch U, Ebner T, et al. A review on telmisartran: a novel, long-acting angiotensin II receptor antagonist. Cardiovasc Drug Rev 2000;18:127-154.
2. Stangier J, Su CA, Schondorfer G, Roth W. Pharmacokinetics and safety of intravenous and oral telmisartan 20 and 120mg in subjects with hepatic impairment compared with healthy volunteers. J Clin Pharmacol 2000;40:1355-1364.
3. 14C]telmisartan in healthy volunteers. J Clin Pharmacol 2000;40:1312-1322.
4. Abe T, Kakyo M, Tokui T, Nakagomi R, Nishio T, Nakai D, et al. Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1. J Biol Chem 1999;274:17159-17163.
5. Hsiang B, Zhu Y, Wang Z, Wu Y, Sasseville V, Yang WP, et al. A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem 1999;274:37161-37168.
6. Konig J, Cui Y, Nies AT, Keppler D. A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. Am J Physiol Gastrointest Liver Physiol 2000;278:G156-G164. (Pubitemid 30108080)
7. Konig J, Cui Y, Nies AT, Keppler D. Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide. J Biol Chem 2000;275:23161-23168. (Pubitemid 30646210)
8. Ishiguro N, Maeda K, Kishimoto W, Saito A, Harada A, Ebner T, et al. Predominant contribution of OATP1B3 to the hepatic uptake of telmisartan, an angiotensin II receptor antagonist, in humans. Drug Metab Dispos 2006;34:1109-1115.
9. Ishiguro N, Maeda K, Saito A, Kishimoto W, Matsushima S, Ebner T, et al. Establishment of a set of double transfectants coexpressing organic anion transporting polypeptide 1B3 and hepatic efflux transporters for the characterization of the hepatobiliary transport of telmisartan acylglucuronide. Drug Metab Dispos 2008;36:796-805. (Pubitemid 351468387)
10. Ieiri I, Higuchi S, Sugiyama Y. Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs. Expert Opin Drug Metab Toxicol 2009;5:703-729.
11. Miura M, Satoh S, Inoue K, Kagaya H, Saito M, Inoue T, et al. Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol 2007;63:1161-1169. (Pubitemid 350112768)
12. Smith NF, Marsh S, Scott-Horton TJ, Hamada A, Mielke S, Mross K, et al. Variants in the SLCO1B3 gene: interethnic distribution and association with paclitaxel pharmacokinetics. Clin Pharmacol Ther 2007;81:76-82. (Pubitemid 46050869)
13. Kiyotani K, Mushiroda T, Kubo M, Zembutsu H, Sugiyama Y, Nakamura Y. Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia. Cancer Sci 2008;99:967-972. (Pubitemid 351997599)
14. Hoffmeyer S, Burk O, Von Richter O, Arnold HP, Brockmoller J, Johne A, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000;97:3473-3478. (Pubitemid 30183327)
15. Meyer zu Schwabedissen HE, Jedlitschky G, Gratz M, Haenisch S, Linnemann K, Fusch C, et al. Variable expression of MRP2 (ABCC2) in human placenta: influence of gestational age and cellular differentiation. Drug Metab Dispos 2005;33:896-904. (Pubitemid 41002769)
16. Sparreboom A, Gelderblom H, Marsh S, Ahluwalia R, Obach R, Principe P, et al. Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype. Clin Pharmacol Ther 2004;76:38-44. (Pubitemid 38844732)
17. Sparreboom A, Loos WJ, Burger H, Sissung TM, Verweij J, Figg WD, et al. Effect of ABCG2 genotype on the oral bioavailability of topotecan. Cancer Biol Ther 2005;4:650-658.
18. *2 polymorphisms on UGT1A1 or UGT2B7 activities and protein expression in human liver microsomes. Br J Clin Pharmacol 2007;64:458-468. (Pubitemid 47404310)
19. Ando Y, Saka H, Asai G, Sugiura S, Shimokata K, Kamataki T. UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan. Ann Oncol 1998;9:845-847. (Pubitemid 28440442)
20. Yamamoto N, Takahashi T, Kunikane H, Masuda N, Eguchi K, Shibuya M, et al. Phase I/II pharmacokinetic and pharmacogenomic study of UGT1A1 polymorphism in elderly patients with advanced non-small cell lung cancer treated with irinotecan. Clin Pharmacol Ther 2009;85:149-154.
21. Levesque E, Delage R, Benoit-Biancamano MO, Caron P, Bernard O, Couture F, et al. The impact of UGT1A8, UGT1A9, and UGT2B7 genetic polymorphisms on the pharmacokinetic profile of mycophenolic acid after a single oral dose in healthy volunteers. Clin Pharmacol Ther 2007;81:392-400. (Pubitemid 46364482)
22. Young CL, Dias VC, Stangier J. Multiple-dose pharmacokinetics of telmisartan and of hydrochlorothiazide following concurrent administration in healthy subjects. J Clin Pharmacol 2000;40:1323-1330.
23. Mast A, De Arruda M. Invader assay for single-nucleotide polymorphism genotyping and gene copy number evaluation. Methods Mol Biol 2006;335:173-186.
24. Yamaoka K, Tanigawara Y, Nakagawa T, Uno T. A pharmacokinetic analysis program (multi) for microcomputer. J Pharmacobiodyn 1981;4:879-885. (Pubitemid 12174128)
25. Hamada A, Sissung T, Price DK, Danesi R, Chau CH, Sharifi N, et al. Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer. Clin Cancer Res 2008;14:3312-3318.
26. Nishino A, Kato Y, Igarashi T, Sugiyama Y. Both cMOAT/MRP2 and another unknown transporter (s) are responsible for the biliary excretion of glucuronide conjugate of the nonpeptide angiotensin II antagonist, telmisartan. Drug Metab Dispos 2000;28:1146-1148.
27. Mackenzie PI, Owens IS, Burchell B, Bock KW, Bairoch A, Belanger A, et al. The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence. Pharmacogenetics 1997;7:255-269. (Pubitemid 27358064)
28. Higuchi K, Kobayashi Y, Kuroda M, Tanaka Y, Itani T, Araki J, et al. Modulation of organic anion transporting polypeptide 1 and multidrug resistance protein 3 expression in the liver and kidney of Gunn rats. Hepatol Res 2004;29:60-66. (Pubitemid 38594513)
29. Riedmaier S, Klein K, Hofmann U, Keskitalo JE, Neuvonen PJ, Schwab M, et al. UDP-glucuronosyltransferase (UGT) polymorphisms affect atorvastatin lactonization in vitro and in vivo. Clin Pharmacol Ther 2010;87:65-73.
30. Lankisch TO, Gillman TC, Erichsen TJ, Ehmer U, Kalthoff S, Freiberg N, et al. Aryl hydrocarbon receptor-mediated regulation of the human estrogen and bile acid UDP-glucuronosyltransferase 1A3 gene. Arch Toxicol 2008;82:573-582.
31. Togawa H, Shinkai S, Mizutani T. Induction of human UGT1A1 by bilirubin through AhR dependent pathway. Drug Metab Lett 2008;2:231-237.